Search clinical trials for: HM95573, cetuximab

Total 3075 results

UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); National Center for Research... and other collaborators

Completed

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Breast Cancer

United States
Central European Cooperative Oncology Group

Completed

Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer (CORE 2)

Colorectal Cancer

Israel, Austria, Croatia, Greece, Serbia, Bosnia and Herzegovina, Bulgaria, Estonia, Hungary, Latvia, Romania, Slovakia, Slovenia
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer

Head and Neck Cancer

United States
Jiang Feng

Recruiting

Neoadjuvant SBRT in Localized Advanced HNSCC

Head and Neck Squamous Carcinoma

China
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (CHANCE)

Squamous Cell Carcinoma of the Head and Neck

China
Dr. Carl Schimanski

Unknown

FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema (DERMATUX)

Colorectal Cancer Metastatic

Germany
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy

Lung Cancer
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

Colorectal Neoplasms | Neoplasm | Metastases

United States, Canada
Institut du Cancer de Montpellier - Val d'Aurelle
Merck Serono International SA

Completed

Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer (ESTER)

Colorectal Cancer

France
Eli Lilly and Company

Completed

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

Colorectal Cancer

United States
Georgetown University

Terminated

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Head and Neck Squamous Cell Cancer

United States
University of Colorado, Denver

Completed

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

Recurrent Head and Neck Cancer

United States
Eben Rosenthal
National Cancer Institute (NCI)

Terminated

Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery

Malignant Glioma | Brain Neoplasm

United States
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux (2007-01)

HNSCC

France
Bristol-Myers Squibb

Terminated

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Head and Neck Cancer | Neoplasm Metastasis | Colorectal Cancer

United States, Canada
Grupo Español de Tratamiento de Tumores de Cabeza...

Completed

TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.

Head and Neck Cancer

Spain
Wuhan Union Hospital, China

Not yet recruiting

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC (PC-1)

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy

China
Federation Francophone de Cancerologie Digestive
Merck Sharp & Dohme LLC; Pierre Fabre Laboratories

Recruiting

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NEORAF)

Colorectal Cancer | BRAF V600E Mutation Positive

France
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

CRC

China
P.O. Witteveen
Merck KGaA, Darmstadt, Germany

Terminated

Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma (TRACC)

Resectable Esophageal Cancer

Netherlands
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

NSCLC | Advanced Solid Tumor | CRC

United States
SFJ Pharmaceuticals X, LTD.
Merck KGaA, Darmstadt, Germany; AIO-Studien-gGmbH; Academic and Community Cancer... and other collaborators

Withdrawn

Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. (AMELION)

Metastatic Colorectal Cancer
The Christie NHS Foundation Trust

Completed

Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Cancer

United Kingdom
Theagenio Cancer Hospital

Unknown

Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck

Head and Neck Neoplasms | AJCC Stage III/IV

Greece
Johannes Gutenberg University Mainz
AIO-Studien-gGmbH

Completed

Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer (GC-CIF-2005)

Adenocarcinoma of Stomach or Esophagogastric Junction

Germany
Georgetown University
GlaxoSmithKline

Completed

Lapatinib and Cetuximab in Patients With Solid Tumors (TYKERB-ITUX 1)

Head and Neck Cancer | Colorectal Cancer | Lung Cancer

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

Sintilimab, Cetuximab, Regorafenib,Combine,mCRC

China
NCIC Clinical Trials Group
Australasian Gastro-Intestinal Trials Group

Completed

Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

Quality of Life | Colorectal Cancer

Canada, Australia
University of California, San Diego
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Nasopharynx Cancer | Head and Neck Squamous Cell Carcinoma | Oropharynx Cancer | Oral Cavity Cancer | Larynx Cancer | HNSCC | Hypopharynx Cancer | Cutaneous Squamous Cell Carcinoma | Lip SCC | Sinonasal Carcinoma

United States
The Netherlands Cancer Institute
Merck KGaA, Darmstadt, Germany

Completed

Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)

Carcinoma, Squamous Cell of Head and Neck

Netherlands
Technische Universität Dresden

Completed

Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Germany
Groupe Oncologie Radiotherapie Tete et Cou
Tumor Study Group Head and Neck

Completed

Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation

Larynx Cancer | Hypopharynx Cancer

France
King Faisal Specialist Hospital & Research Center

Completed

A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer

Colon Rectal Cancer Duke Stage Stageval

Saudi Arabia
Curegenix Inc.
Merck Sharp & Dohme LLC

Recruiting

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Solid Tumors | GI Cancer

United States, Taiwan
Institut du Cancer de Montpellier - Val d'Aurelle

Completed

Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine (THERAPY)

Pancreatic Cancer

France
Masonic Cancer Center, University of Minnesota

Completed

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
University Medical Center Groningen

Completed

Fluorescence Molecular Endoscopy and Molecular Fluorescence-guided Surgery in Locally Advanced Rectal Cancer (TRACT-II)

Rectal Cancer

Netherlands
National Cancer Institute (NCI)

Completed

Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer

Head and Neck Cancer

United States
Institut de Cancérologie de la Loire

Completed

Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

France
US Oncology Research
Eli Lilly and Company; Sanofi

Completed

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

Gastric Cancer Adenocarcinoma Metastatic

United States
Northwell Health

Completed

Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA

GBM | Anaplastic Astrocytoma | Glioblastoma Multiforme (GBM) | ANAPLASTIC ASTROCYTOMA (AOA)

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Head and Neck Cancer | Precancerous Condition

United States, Canada
First Affiliated Hospital of Zhejiang University

Recruiting

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

Squamous Cell Carcinoma of Head and Neck

China
Wuhan Union Hospital, China

Recruiting

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

Colorectal Neoplasms Malignant

China
University Medical Center Groningen

Recruiting

Real-time Margin Assessment in Head and Neck Cancer (LIGHTNING)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

Netherlands
Fudan University

Completed

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
Shanghai Minimally Invasive Surgery Center

Recruiting

Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy

Rectal Cancer | Radiotherapy | Neoadjuvant Treatment | Cetuximab

China
Fudan University

Not yet recruiting

Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Colorectal Cancer | Liver Metastases

China
Azienda USL 4 Prato
Università degli Studi di Brescia

Terminated

Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (CTXMAB+RT)

Head and Neck Neoplasms | Pharyngeal Neoplasms | Mouth Neoplasms | Laryngeal Neoplasms

Italy

Search clinical trials for: HM95573, cetuximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations